Megan McNerney, MD, PhD, assistant professor of pathology, studies myeloid neoplasms, a group of diseases in the blood or bone marrow in which excess cells are produced.
Her research focuses on understanding the underlying genetic abnormalities that cause these diseases, which is essential for identifying new treatment options.
A major goal of McNerney’s work is to use next-generation DNA sequencing to identify cancer mutations to guide patient diagnosis and treatment decisions.
Blase Polite, MD, associate professor of medicine, has expertise in the treatment of gastrointestinal malignancies, with a particular focus on colon, rectal, and anal cancers, and neuroendocrine (carcinoid) tumors.
In addition to his clinical responsibilities, Dr. Polite’s research focuses on understanding racial and ethnic differences in colon cancer outcomes, especially the psychological, social, and spiritual needs of each patient. The Board’s support helped Polite launch a 5-year study to discover the causes of racial and ethnic disparities in colon cancer diagnosis and outcomes.
Mark Applebaum, MD, clinical instructor of pediatrics, is an expert in childhood cancers and blood diseases. He has a special interest in the treatment of neuroblastoma, sarcomas and solid tumors.
Through this research, Dr. Applebaum has helped develop risk-based guidelines for long-term follow-up of childhood and adolescent cancer survivors for subsequent malignant neoplasms and other adverse health outcomes based on the primary disease, treatment exposure, and established therapy-related morbidities and mortality observed in the survivorship population.
Nita Karnik Lee, MD, PhD, assistant professor of obstetrics/gynecology, specializes in the diagnosis and treatment of women with gynecologic malignancies.
Her research interests include cancer survivorship, cancer disparities, and clinical trials focusing on new therapies for ovarian, uterine and cervical cancers. She is an active member of the Gynecologic Oncology Group (GOG), a cooperative research group supported by the National Cancer Institute.